New Launch Site Discount — 50% off sitewide· +10% with Bank Pay
1 / 6
Cognitive & Neurological Research · Metabolic Peptides
ARA-290
$85.00$42.50Save 50%
Out of stock
99% Pure | Multi Dose | Finished in the USA
ARA-290 (Cibinetide) is an 11-amino-acid synthetic peptide derived from erythropoietin that selectively activates the innate repair receptor (IRR) without stimulating red-blood-cell production. Widely used in preclinical models of neuroinflammation, organ protection, and metabolic regulation, ARA-290 offers precise IRR engagement and robust cytoprotective signaling.
For Research Use Only. Not for human consumption or therapeutic treatment.
99% Pure | Multi Dose | Finished in the USA
ARA-290 (Cibinetide) is an 11-amino-acid synthetic peptide derived from erythropoietin that selectively activates the innate repair receptor (IRR) without stimulating red-blood-cell production. Widely used in preclinical models of neuroinflammation, organ protection, and metabolic regulation, ARA-290 offers precise IRR engagement and robust cytoprotective signaling. Each 16 mg vial is verified at ≥99% purity by HPLC, screened for endotoxin (<0.1 EU/mg), and delivered with a full Certificate of Analysis.
Do not use regular BAC water with ARA-290.
It can become cloudy or gel-like when reconstituted with bacteriostatic water (BAC) due to its hydrophobic nature and lower solubility.
Using phosphate-buffered saline (PBS) instead of BAC is often recommended to improve solubility and prevent these issues.
What Is ARA-290?
ARA-290, also known as Cibinetide, is a lab-engineered 11-amino-acid peptide fragment of erythropoietin that selectively engages the innate repair receptor (IRR). Unlike full-length EPO, ARA-290 triggers cytoprotective and anti-inflammatory pathways without stimulating erythropoiesis. In preclinical research, it’s applied to neural, cardiovascular, renal, and metabolic models to explore mechanisms of tissue protection, inflammation modulation, and cell-survival signaling.
Why Choose ARA-290?
Researchers choose ARA-290 for its unmatched selectivity: it binds the IRR to activate PI3K/Akt and STAT3 pathways that promote cell survival, reduce inflammatory damage, and enhance tissue repair. Its small size ensures rapid tissue penetration and consistent receptor engagement. Each vial is produced under, cGMP-like standards and validated by HPLC (>99% purity), MS/MS sequence confirmation, and endotoxin testing—guaranteeing reproducible results across neural, cardiac, and metabolic study designs.
What Sets ARA-290 Apart?
Unlike broader cytokine-mimetic peptides, ARA-290 isolates the reparative arm of EPO signaling via the IRR, without engaging hematopoietic signaling. This targeted action enables clear investigation of cytoprotection in models of ischemia, neurodegeneration, and metabolic stress. Coupled with its demonstrated stability in both lyophilized and reconstituted forms, ARA-290 stands out as a precision tool for dissecting IRR-mediated tissue-repair and anti-inflammatory mechanisms.
Research observations
01
IRR-Mediated Neuroprotection
In rodent models of neural injury, ARA-290 reduces microglial activation and preserves neuronal viability via innate repair receptor signaling.
02
Tissue-Protective Signaling
ARA-290 activates anti-apoptotic pathways (e.g., Akt phosphorylation) in ischemia–reperfusion assays, limiting cell death in heart, kidney, and liver explants.
03
Anti-Inflammatory Modulation
Preclinical studies show ARA-290 lowers pro-inflammatory cytokines (TNF-α, IL-6) in macrophage and endothelial cultures, modeling resolution of acute inflammation.
04
Metabolic Regulation Insights
ARA-290 enhances insulin-sensitivity markers in adipocyte and hepatocyte assays, offering a tool for dissecting IRR-driven metabolic pathways.
05
Wound Healing Acceleration
In ex vivo skin models, ARA-290 promotes keratinocyte migration and matrix remodeling—accelerating wound-closure kinetics by up to 40%.
06
Lab-Grade Handling & Stability
Reconstitute ARA-290 in Sterile Water for Injection (SWFI). Store lyophilized at –20 °C; keep reconstituted peptide at 2–8 °C and use within 7 days for >98% integrity.
Test date on certificate
1 report
CompoundARA-290
Research areaCognitive & Neurological Research, Metabolic Peptides, Focus & Cognition Research, CNS & Neuropeptide Research, Mitochondrial & Metabolic Pathway Research
FormatLyophilised powder, sealed glass vial
Sizes16mg
Reconstituted shelf life30 days at 2–8°C
Independent laboratoryFreedom Diagnostics and Kovera
Lab reports on file1 report
Ships fromSaint Petersburg, FL and California
DispatchWithin 24 hours
ARA-290 is an 11-amino-acid EPO fragment that activates the innate repair receptor for tissue-protective signaling in research models.
By engaging the IRR, ARA-290 downregulates TNF-α and IL-6 in macrophage and endothelial assays, modeling inflammation resolution.
Neural-injury, cardiac-ischemia, renal-protection, wound-healing, and metabolic-regulation studies frequently employ ARA-290.
Reconstitute in Sterile Water for Injection (SWFI), then use within 7 days at 2–8 °C.
Store lyophilized at –20 °C. Reconstituted solutions remain stable at 2–8 °C for up to 7 days with >98% peptide integrity.
No. ARA-290 selectively activates the IRR and does not engage erythropoietic pathways.
In vitro assays often use 100 nM–10 µM, while in vivo rodent studies use 0.1–1 mg/kg depending on the model.
Yes. It’s frequently co-studied with anti-inflammatory or metabolic peptides like BPC-157 or AOD-9604.
No. ARA-290 is strictly for research use only and is not approved for therapeutic or veterinary applications.
ARA-290 is synthesized and validated by HPLC, MS/MS, and endotoxin screening for consistent research performance.
1 / 6
